128 related articles for article (PubMed ID: 7979310)
1. Evaluation of curative anticryptosporidial activity of paromomycin in a dexamethasone-treated rat model.
Verdon R; Polianski J; Gaudebout C; Marche C; Garry L; Pocidalo JJ
Antimicrob Agents Chemother; 1994 Jul; 38(7):1681-2. PubMed ID: 7979310
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of high-dose regimen of paromomycin against cryptosporidiosis in the dexamethasone-treated rat model.
Verdon R; Polianski J; Gaudebout C; Marche C; Garry L; Carbon C; Pocidalo JJ
Antimicrob Agents Chemother; 1995 Sep; 39(9):2155-7. PubMed ID: 8540737
[TBL] [Abstract][Full Text] [Related]
3. A comparison of anticryptosporidial activity of paromomycin with that of other aminoglycosides and azithromycin in immunosuppressed rats.
Rehg JE
J Infect Dis; 1994 Oct; 170(4):934-8. PubMed ID: 7930738
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting anticryptosporidial activity of nitazoxanide in an immunosuppressed rat model.
Li X; Brasseur P; Agnamey P; Leméteil D; Favennec L; Ballet JJ; Rossignol JF
Folia Parasitol (Praha); 2003 Mar; 50(1):19-22. PubMed ID: 12735719
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Mammeri M; Chevillot A; Thomas M; Polack B; Julien C; Marden JP; Auclair E; Vallée I; Adjou KT
Exp Parasitol; 2018 Nov; 194():1-8. PubMed ID: 30237052
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of nitazoxanide and paromomycin in biliary tract cryptosporidiosis in an immunosuppressed gerbil model.
Baishanbo A; Gargala G; Duclos C; François A; Rossignol JF; Ballet JJ; Favennec L
J Antimicrob Chemother; 2006 Feb; 57(2):353-5. PubMed ID: 16361328
[TBL] [Abstract][Full Text] [Related]
7. Chemoprophylaxis of Cryptosporidium parvum infection with paromomycin in kids and immunological study.
Mancassola R; Reperant JM; Naciri M; Chartier C
Antimicrob Agents Chemother; 1995 Jan; 39(1):75-8. PubMed ID: 7695333
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum.
Healey MC; Yang S; Rasmussen KR; Jackson MK; Du C
J Parasitol; 1995 Feb; 81(1):114-6. PubMed ID: 7876965
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model.
Asadpour M; Namazi F; Razavi SM; Nazifi S
Vet Parasitol; 2018 Jan; 250():7-14. PubMed ID: 29329627
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of mangiferin against Cryptosporidium parvum in a neonatal mouse model.
Perrucci S; Fichi G; Buggiani C; Rossi G; Flamini G
Parasitol Res; 2006 Jul; 99(2):184-8. PubMed ID: 16547730
[TBL] [Abstract][Full Text] [Related]
11. Curcumin: A promising treatment for Cryptosporidium parvum infection in immunosuppressed BALB/c mice.
Asadpour M; Namazi F; Razavi SM; Nazifi S
Exp Parasitol; 2018 Dec; 195():59-65. PubMed ID: 30385266
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of an animal model system for cryptosporidiosis: therapeutic efficacy of paromomycin and hyperimmune bovine colostrum-immunoglobulin.
Tzipori S; Rand W; Griffiths J; Widmer G; Crabb J
Clin Diagn Lab Immunol; 1994 Jul; 1(4):450-63. PubMed ID: 8556484
[TBL] [Abstract][Full Text] [Related]
13. Comment on: effect of antiretroviral protease inhibitors alone, and in combination with paromomycin, on the excystation, invasion and in vitro development of Cryptosporidium parvum.
Dugue GA
J Antimicrob Chemother; 2004 Feb; 53(2):403; author reply 403. PubMed ID: 14729752
[No Abstract] [Full Text] [Related]
14. [Efficacy of paromomycin sulfate (Humagel) in an AIDS infected patient with intestinal cryptosporidiosis].
Hammel P; Rogeaux O; Diouf ML; Gouyon B; Ruszniewski P; Bernades P
Gastroenterol Clin Biol; 1992; 16(12):1010-1. PubMed ID: 1493891
[No Abstract] [Full Text] [Related]
15. Assessment of candidate anticryptosporidial agents in an immunosuppressed rat model.
Lemeteil D; Roussel F; Favennec L; Ballet JJ; Brasseur P
J Infect Dis; 1993 Mar; 167(3):766-8. PubMed ID: 8440946
[TBL] [Abstract][Full Text] [Related]
16. Field trial on the therapeutic efficacy of paromomycin on natural Cryptosporidium parvum infections in lambs.
Viu M; Quílez J; Sánchez-Acedo C; del Cacho E; López-Bernad F
Vet Parasitol; 2000 Jun; 90(3):163-70. PubMed ID: 10841996
[TBL] [Abstract][Full Text] [Related]
17. New potential therapies for cryptosporidiosis: an analysis of variables affecting drug efficacy.
Rehg J
Folia Parasitol (Praha); 1994; 41(1):23-6. PubMed ID: 8050751
[TBL] [Abstract][Full Text] [Related]
18. Cost-effective In Vivo and In Vitro Mouse Models for Evaluating Anticryptosporidial Drug Efficacy: Assessing Vorinostat, Docetaxel, and Baicalein.
Liu M; Zhang D; Wang D; Wu X; Zhang Y; Yin J; Zhu G
J Infect Dis; 2023 Nov; 228(10):1430-1440. PubMed ID: 37418629
[TBL] [Abstract][Full Text] [Related]
19. Development of particulate drug formulation against C. parvum: Formulation, characterization and in vivo efficacy.
Blanco-García E; Guerrero-Callejas F; Blanco-Méndez J; Gómez-Couso H; Luzardo-Álvarez A
Eur J Pharm Sci; 2016 Sep; 92():74-85. PubMed ID: 27381880
[TBL] [Abstract][Full Text] [Related]
20. The gamma interferon gene knockout mouse: a highly sensitive model for evaluation of therapeutic agents against Cryptosporidium parvum.
Griffiths JK; Theodos C; Paris M; Tzipori S
J Clin Microbiol; 1998 Sep; 36(9):2503-8. PubMed ID: 9705383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
